A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, with patients who received the one-time IV therapy with more than 90% decrease in bleeding events 2 to 3 years after treatment, reports the early clinical trial in the New England Journal of Medicine.

A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, with patients who received the one-time IV therapy with more than 90% decrease in bleeding events 2 to 3 years after treatment, reports the early clinical trial in the New England Journal of Medicine.
A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, with patients who received the one-time IV therapy with more than 90% decrease in bleeding events 2 to 3 years after treatment, reports the early clinical trial in the New England Journal of Medicine. submitted by /u/mvea
[link] [comments]
https://ift.tt/2MQwxbg January 03, 2020 at 10:30AM https://ift.tt/1R552o9
by at
Tags

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)